Trial Profile
'Primovax' - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Tertomotide (Primary) ; Gemcitabine; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms PrimoVax
- Sponsors Pharmexa
- 31 May 2009 Results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009)
- 13 May 2008 Status changed from recruiting to discontinued based on information from a Pharmexa media release.
- 13 May 2008 Enrolment was terminated after a preliminary analysis of data from 174 patients showed no additional survival benefits of combination therapy compared with monotherapy. Final conclusions will be based on full data analyses and further follow-up.